Medtronic Will Pay Edwards More Than $1 Billion To Settle TAVR Dispute
This article was originally published in The Gray Sheet
A settlement between the two companies dismissing all pending patent litigation related to transcatheter valve replacement technologies ends years of legal wrangling and ensures that the U.S. TAVR market will have at least two competitors.
You may also be interested in...
Edwards Lifesciences and Boston Scientific announced this week that the firms had resolved an ongoing global patent dispute.
The US Patent & Trademark Office has found three grounds on which to review four claims in a Boston Scientific TAVR patent being challenged by Edwards Lifesciences. The companies have seen mixed recent verdicts in European bodies on related patent disputes.
More patent litigation is emerging in the transcatheter aortic valve replacement space with two recent lawsuits alleging that Edwards Lifesciences' Sapien 3 TAVR device and delivery systems violated a total of nine patents held by Boston Scientific.